Skip to main content
A non-invasive heart therapy designed to support patients with CSA, simplify clinical delivery, and deliver better care economics.1
For decades, external counterpulsation (ECP) has offered a non-invasive option for adults with Chronic Stable Angina (CSA) who are no longer candidates for revascularization. Yet legacy ECP systems have remained large, immobile, and difficult to integrate into today’s care environments—limiting patient access and creating workflow challenges for clinics and hospitals.
Wave PRO was clinically tested under the WaveCRESST clinical trial and was shown to be equivalent to predicate ECP therapy devices, as well as showing a preference for patient comfort and less set up time with a calf-only design for care providers.1
Wave PROTM delivers external counterpulsation therapy through lightweight calf sleeves that inflate and deflate in sequence, synchronized with the heart’s resting phase1. The system uses fingertip PPG sensing and an automated timing algorithm to ensure each compression occurs at the right moment in the cardiac cycle. This simple, automated process helps support healthy blood flow back to the heart. The Wave PROTM delivers results without surgery, without recovery time, and with minimal staff involvement.
Wave PROTM makes clinically validated ECP therapy more accessible for patients and easier to deliver across modern care settings.